INCY vs ZBH: fair value comparison
Incyte Corporation and Zimmer Biomet Holdings, Inc. · Updated 2026-09-07
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, INCY currently sits closer to the top of our discount ranking. INCY carries the stronger quality grade.
| INCY | ZBH | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $126.75 | $98.07 |
| 12-month range | $93.48–$125.01 | $82.90–$100.56 |
| Sector rank | #37 of 113 Healthcare | #39 of 113 Healthcare |
| Quality grade | A | B |
| Momentum grade | — | B |
| Leverage | Low | Moderate |
| Margin trend | Stable | Stable |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: INCY fair value analysis · ZBH fair value analysis